Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04ERQ
|
|||
| Former ID |
DIB003029
|
|||
| Drug Name |
CXD-101
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 1 | [1] | |
| Company |
AstraZeneca plc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C24H29N5O
|
|||
| Canonical SMILES |
CC1=NN(C=C1CN2CCC(CC2)C3=CC=C(C=C3)C(=O)NC4=CC=CC=C4N)C
|
|||
| InChI |
1S/C24H29N5O/c1-17-21(15-28(2)27-17)16-29-13-11-19(12-14-29)18-7-9-20(10-8-18)24(30)26-23-6-4-3-5-22(23)25/h3-10,15,19H,11-14,16,25H2,1-2H3,(H,26,30)
|
|||
| InChIKey |
JHDZMASHNBKTPS-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 934828-12-3
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Histone deacetylase (HDAC) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01977638) Phase 1 Trial of CXD101 in Patients With Advanced Cancer. U.S. National Institutes of Health. | |||
| REF 2 | Activity of the new cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa isolates from chronically-infected cystic fibrosis patients. Clin Microbiol Infect. 2010 Sep;16(9):1482-7. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.